Genome Editing and Nanotechnology-Based Treatment for Breast Cancers
- 1st Edition - October 1, 2025
- Authors: Amna Aqeel, Avaria Zafar
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 2 2 2 7 4 - 0
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 2 2 7 5 - 7
Genome Editing and Nanotechnology-Based Treatment for Breast Cancers delves deeply into the multifaceted nature of breast cancer. It begins with a thorough introduction to the di… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteGenome Editing and Nanotechnology-Based Treatment for Breast Cancers delves deeply into the multifaceted nature of breast cancer. It begins with a thorough introduction to the disease, detailing its histological and molecular subtypes and then moves on to explain methods for early detection and imaging techniques. The book also explores various treatment options, focusing on innovative technologies like genome editing and nanotechnology. In its nine sections, the book probes the elements that contribute to breast cancer metastasis and discusses the potential of genome editing tools for creating tailor-made drugs.
Users will find this to be a crucial resource for researchers, graduate students in cancer research and bioinformatics, oncologists, and anyone seeking to expand their understanding of the field.
- Provides a comprehensive picture of non-invasive methods for the detection of molecular subtypes of breast cancer
- Gives a rational basis for the assessment of genome editing tools to be used to produce nanoparticle based delivery system
- Summarizes the latest studies and real-world achievements
Researchers and graduate students on cancer research and bioinformatics; oncologistsClinical researchers; pharmaceutical industries
1. Introduction to Breast cancer
2. Histological and Molecular subtypes of breast cancer based on PAM50 RNA-based gene signature
3. Biomarkers-Prognostic parameters for different molecular subtypes of breast cancer
3.1. Status of Carcinoembryonic antigen (CEA) and cancer antigen (CA)
3.2. Hypoxia inducible transcription factors
3.3. Human Epidermal growth factors
3.4. Androgen receptors
3.5. Oestrogen receptor isoforms
3.6. Insulin like growth factor-1 receptor
3.7. Ki67expression
3.8. Progesterone receptor
3.9. Modulation of Nestin expression
3.10. E-cadherin
4. Tumor suppressor genes-leading cause of breast cancer
4.1. P53 mutation
4.2. ErbB-2 overexpression
4.3. PI3KCA mutation
4.4. E-cadherin
4.5. ATP7A Overexpression
5. Single nucleotide polymorphism in breast cancer susceptibility genes
5.1. CDKN2A and AKT1 variation
5.2. Role of miRNA SNPs in Breast cancer susceptibility
5.3. Polymorphism of CCND1, CDH1 and NQO2 genes
6. Metabolomic profiling of breast cancer patient
6.1. Plasma amino acid profile
6.2. Regulation of mitochondrial dynamics in migration and invasion of breast cancer
6.3. Dynamics in Aerobic glycolysis (Warburg Effect) and insulin resistance
6.4. Role of Pentose phosphate pathways (PPP) in metastasis of breast cancer
6.5. Alteration in de novo lipogenesis, glutaminolysis and glycerophospholipid metabolism
6.6. Modification in signaling pathways
7. Non-invasive methods for early detection of breast cancer
7.1. Urine sampling
7.2. Exhaled breath sampling
8. Breast cancer imaging techniques
8.1. 3D-imaging of breast cancer/ Deep learning approaches
8.2. Dual-modality photoacoustic tomography
8.3. Prediction of breast cancer molecular subtypes using radiomics signature
8.4. Nuclear medicine imaging
9. Possible treatments of breast cancer
9.1. Chemotherapeutic approaches for the treatment of breast cancer
9.1.1. Radio-chemotherapy
9.1.2. Endocrine chemotherapy
9.1.3. Neoadjuvant chemotherapy
9.1.4. Concurrent chemotherapy
9.2. Liposomal mediated treatment of breast cancer
9.3. Nano-particle based therapeutic approaches
10. Genome based targeted therapies for treatment of breast cancer
11. CRISPR technology for diagnosis of breast cancer
11.1. Role of CRISPR technology in immuno-therapeutics of breast cancer
11.2. CRISPR-Cas9 based editing of tumor inducing genes
11.3. Possible targets of CRISPR-Cas 9 system against drug resistant molecules in breast cancer
11.4. Application of Nano-particles based delivery system for CRISPR/Cas 9
12. Pharmacokinetics and pharmacodynamics of nano-particles based delivery systems.
2. Histological and Molecular subtypes of breast cancer based on PAM50 RNA-based gene signature
3. Biomarkers-Prognostic parameters for different molecular subtypes of breast cancer
3.1. Status of Carcinoembryonic antigen (CEA) and cancer antigen (CA)
3.2. Hypoxia inducible transcription factors
3.3. Human Epidermal growth factors
3.4. Androgen receptors
3.5. Oestrogen receptor isoforms
3.6. Insulin like growth factor-1 receptor
3.7. Ki67expression
3.8. Progesterone receptor
3.9. Modulation of Nestin expression
3.10. E-cadherin
4. Tumor suppressor genes-leading cause of breast cancer
4.1. P53 mutation
4.2. ErbB-2 overexpression
4.3. PI3KCA mutation
4.4. E-cadherin
4.5. ATP7A Overexpression
5. Single nucleotide polymorphism in breast cancer susceptibility genes
5.1. CDKN2A and AKT1 variation
5.2. Role of miRNA SNPs in Breast cancer susceptibility
5.3. Polymorphism of CCND1, CDH1 and NQO2 genes
6. Metabolomic profiling of breast cancer patient
6.1. Plasma amino acid profile
6.2. Regulation of mitochondrial dynamics in migration and invasion of breast cancer
6.3. Dynamics in Aerobic glycolysis (Warburg Effect) and insulin resistance
6.4. Role of Pentose phosphate pathways (PPP) in metastasis of breast cancer
6.5. Alteration in de novo lipogenesis, glutaminolysis and glycerophospholipid metabolism
6.6. Modification in signaling pathways
7. Non-invasive methods for early detection of breast cancer
7.1. Urine sampling
7.2. Exhaled breath sampling
8. Breast cancer imaging techniques
8.1. 3D-imaging of breast cancer/ Deep learning approaches
8.2. Dual-modality photoacoustic tomography
8.3. Prediction of breast cancer molecular subtypes using radiomics signature
8.4. Nuclear medicine imaging
9. Possible treatments of breast cancer
9.1. Chemotherapeutic approaches for the treatment of breast cancer
9.1.1. Radio-chemotherapy
9.1.2. Endocrine chemotherapy
9.1.3. Neoadjuvant chemotherapy
9.1.4. Concurrent chemotherapy
9.2. Liposomal mediated treatment of breast cancer
9.3. Nano-particle based therapeutic approaches
10. Genome based targeted therapies for treatment of breast cancer
11. CRISPR technology for diagnosis of breast cancer
11.1. Role of CRISPR technology in immuno-therapeutics of breast cancer
11.2. CRISPR-Cas9 based editing of tumor inducing genes
11.3. Possible targets of CRISPR-Cas 9 system against drug resistant molecules in breast cancer
11.4. Application of Nano-particles based delivery system for CRISPR/Cas 9
12. Pharmacokinetics and pharmacodynamics of nano-particles based delivery systems.
- No. of pages: 200
- Language: English
- Edition: 1
- Published: October 1, 2025
- Imprint: Academic Press
- Paperback ISBN: 9780443222740
- eBook ISBN: 9780443222757
AA
Amna Aqeel
Ms. Amna Aqeel has completed (M.Phil.) in Biotechnology from Government College University (GCU) Lahore, Pakistan with distinction. She has coordinated with Assistant Professor as a Teaching Assistant at GCU Lahore to teach subjects like “Medical Biotechnology” and “Molecular Techniques in Molecular Biology & Biotechnology”. She assisted in teaching Medical Biotechnology at the BS level, which allowed her to learn about the formulation of personalized medicines for cancers. As a budding researcher she has published 12 scientific papers in reputable international journals and works on research and review papers to make a mark in the field of Biotechnology.
Affiliations and expertise
Biotechnology Institute of Industrial Biotechnology Government College University, Lahore, PakistanAZ
Avaria Zafar
Ms. Javaria Zafar has completed her M.Phil. Biotechnology from Government College University (GCU) Lahore with a research dissertation on “Improved catalytic efficiency of bacterial glutamic acid decarboxylase by immobilization on mesoporous silica nanoparticles for stability in the γ-aminobutyric acid synthesis.” This research aimed to provide the basis for the rational drug development of Alzheimer’s disease to restore the level of GABA in the brain. She has published five research and review articles in reputable international journals with an impact of 13. Being a part of the STEM fraternity, she is dedicated to ensuring a healthy life and an inclusive work ecosystem for women in Pakistan. For this purpose, she has recently joined the UNDP’s Mover’s Program as a Facilitator to work on gender disparity and climate justice in Pakistan. In a nutshell, she has the vision to advocate for and contribute to the SDGs on a national and international scale
Affiliations and expertise
Biotechnology Institute of Industrial Biotechnology Government College University, Lahore, Pakistan